Julie R. Graham

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal et al. · JAMA Oncology · 2019 · 560 citations · Full text

Medicine, Oncology, Pharmacology +17

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

Shaveta Vinayak, Sara M. Tolaney, Lee S. Schwartzberg et al. · JAMA Oncology · 2019 · 433 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

Anniina Färkkilä, D. Gulhan, Julia Casado et al. · Nature Communications · 2020 · 341 citations · Full text

Medicine, Immunology, Oncology +17

Serine Protease HTRA1 Antagonizes Transforming Growth Factor-β Signaling by Cleaving Its Receptors and Loss of HTRA1 In Vivo Enhances Bone Formation

Julie R. Graham, Angela Chamberland, Qingcong Lin et al. · PLoS ONE · 2013 · 71 citations · Full text

Medicine, Biochemistry, Molecular Biology +10

mRNA Degradation Plays a Significant Role in the Program of Gene Expression Regulated by Phosphatidylinositol 3-Kinase Signaling

Julie R. Graham, Melissa Hendershott, Jolyon Terragni et al. · Molecular and Cellular Biology · 2010 · 47 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17